9 active not recruiting, 3 completed, 1 recruiting, 1 terminated. 14 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 8, Completed 3, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Trametinib Dimethyl Sulfoxide: new trials by email Literature Review of Trametinib Dimethyl Sulfoxide trials Research Report on Trametinib Dimethyl Sulfoxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma | Phase 2 | Recruiting | University of California, San Francisco | 96 | 2025-11-07 | 2026-10-22 |
| Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 16 | 2021-08-19 | 2026-10-14 |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 5 | 2021-06-01 | 2026-10-06 |
| Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture - Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2020-02-20 | 2026-07-10 |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration Dabrafenib, Trametinib, Hydroxychloroquine - Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration | Phase 1 / Phase 2 | Active not recruiting | Pediatric Brain Tumor Consortium | 57 | 2020-01-17 | 2026-09-11 |
| Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration - Erdheim-Chester Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-01-04 | 2021-03-17 | |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) Trametinib Dimethyl Sulfoxide - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2016-02-25 | 2026-07-17 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) Trametinib Dimethyl Sulfoxide - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 4 | 2016-02-25 | 2026-07-17 |
| Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 44 | 2016-01-04 | 2026-06-12 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 267 | 2015-09-08 | 2026-10-22 |
| Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) Trametinib Dimethyl Sulfoxide - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2015-08-12 | 2026-05-07 |
| Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide - BRAF V600E Mutation | Phase 2 | Completed | National Human Genome Research Institute (NHGRI) | 9 | 2014-11-01 | 2021-08-31 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 280 | 2014-09-19 | 2026-10-22 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer Biopsy, Biospecimen Collection, Computed Tomography - Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2013-10-08 | 2025-01-14 |
Hematologic Neoplasms (5) · Lymphoma (4) · Melanoma (4) · Multiple Myeloma (4) · Glioma (2) · Astrocytoma (1) · Cystadenocarcinoma, Serous (1) · Erdheim-Chester Disease (1) · Glioblastoma (1) · Histiocytosis (1) · Histiocytosis, Non-Langerhans-Cell (1) · Neoplasm Metastasis (1)
National Cancer Institute (NCI) (11) · ECOG-ACRIN Cancer Research Group (1) · National Human Genome Research Institute (NHGRI) (1) · Pediatric Brain Tumor Consortium (1) · University of California, San Francisco (1)
United States (15) · Puerto Rico (1) · United Kingdom (1)
Jason J Luke (2) · Alain P Algazi (1) · Antoni Ribas (1) · David M Gershenson (1) · Douglas B Johnson (1) · Erin R Macrae (1) · Filip Janku (1) · Lindsey Hoffman, DO (1) · Michael B Atkins (1) · Ravi Amaravadi (1) · Rishi R Lulla (1) · Sabine Mueller, MD, PHD (1) · Tanner M Johanns (1) · William A Gahl, M.D. (1)
PMID 29784747, PMID 33020646, PMID 34331515, PMID 34416167, PMID 35123694, PMID 36166727, PMID 36877575, PMID 38261444, PMID 41533998
U10CA180820 (6), U24CA196172 (4), U10CA032102 (2), U10CA180888 (2), P30CA016672 (1), P50CA083639 (1), U10CA180830 (1), U10CA180868 (1), U10CA180886 (1), UM1CA081457 (1), UM1CA186689 (1), UM1CA186704 (1)